Antioxidative effects of fluvastatin and its metabolites against DNA damage in streptozotocin-treated mice

Food and Chemical Toxicology

Volumn 40, Issue 10, 2002, Pages 1415-1422

  Imaeda, A ^a   Kaneko, T ^b   Aoki, T ^a   Kondo, Y ^a   Nakamura, N ^c   Nagase, H ^d   Yoshikawa, T ^c  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

8 Hydroxy 2 deoxyguanosine; Antioxidant; Fluvastatin; Oxidative DNA damage; Single cell gel electrophoresis assay; Streptozotocin

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALANINE AMINOTRANSFERASE; ANTIOXIDANT; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; DRUG METABOLITE; FLUINDOSTATIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; M 2; M 4; PRAVASTATIN; PROBUCOL; SIMVASTATIN; SOEDOMYCIN; STREPTOZOCIN; TROLOX C; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; GEL ELECTROPHORESIS; GENOTOXICITY; GLUCOSE BLOOD LEVEL; LIVER TOXICITY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; UREA NITROGEN BLOOD LEVEL;

ALANINE TRANSAMINASE; ANIMALS; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; BLOOD UREA NITROGEN; CREATININE; DEOXYGUANOSINE; DIABETES MELLITUS, EXPERIMENTAL; DNA; DNA DAMAGE; FATTY ACIDS, MONOUNSATURATED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; KIDNEY; LIVER; MALE; MICE; MICE, INBRED ICR; OXIDATIVE STRESS; PRAVASTATIN; SIMVASTATIN; WEIGHT GAIN;

EID: 0036774975     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(02)00111-4     Document Type: Article

References (32)

1. Ames B.N. Dietary carcinogens and anticarcinogens. Science. 221:1983;1256-1264.
2. Ames B.N. Endogeneous oxidative DNA damage, aging, and cancer. Free Radical Research Communications. 7:1989;121-128.
3. Anderson D., Phillips B.J., Yu T.W., Edwards A.J., Ayesh R., Butterworth K.R. The effect of vitamin C supplementation on biomarkers of oxygen radical generated damage in human volunteers with low or high cholesterol levels. Environmental Molecular Mutagenesis. 30:1997;161-174.
4. Dain J.G., Fu E., Gorski J., Nicoletti J., Scallen T.J. Biotransformation of fluvastatin sodium in humans. Drug Metabolism and Disposition. 21(4):1993;567-572.
5. Fairbairn D.W., Olive P.L., O'Neill K.L. The comet assay: a comprehensive review. Mutation Research. 339:1995;37-59.
6. Hiramatsu M., Liu J., Edamatsu R., Ohba S., Kadowaki D., Mori A. Probucol scavenged 1,1-diphenyl-2-picrylhydrazyl radicals and inhibited formation of tiobarbituric acid reactive substances. Free Radical Biology and Medicine. 16:1994;201-206.
7. Hussein O., Schlezinger S., Rosenblat M., Keidar S., Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis. 128:1997;11-18.
8. Imaeda A., Aoki T., Kondo Y., Hori M. Effects of antioxidants on the mutagenicity of reactive oxygen species-generating systems towards Salmonella typhimurium TA102 and TA104 strains. Environmental Mutagen Research. 22:2000;1-7.
9. Imaeda A., Aoki T., Kondo Y., Hori M., Ogata M., Obayashi H., Hasegawa G., Nakamura N., Tokuda K., Nishino H., Yoshikawa T., Kondo M. Protective effects of fluvastatin against reactive oxygen species induced DNA damage and mutagenesis. Free Radical Research. 34:2001;33-44.
10. Imaeda A., Tanigawa T., Aoki T., Kondo Y., Nakamura N., Yoshikawa T. Antioxidative effects of fluvastatin and its metabolites against oxidative DNA damage in mammalian cultured cells. Free Radical Research. 35:2001;789-801.
11. Imaeda A., Kaneko T., Aoki T., Kondo Y., Nagase H. The DNA damage and the effect of antioxidants in streptozotocin-treated mice. Food and Chemical Toxicology. 40:2002;979-987.
12. Ishino A., Mita S., Watanabe S., Sakagami H. Effect of anticancer drugs, metals and antioxidants on cytotoxic activity of epigallocatechin gallate. Anticancer Research. 19:1999;4343-4348.
13. Jiann G.L., Michael C.M., William R., Kenneth A., Robert D. The use of the single cell electrophoresis assay in detecting DNA single strand breaks in lung cells in vitro. Toxicology and Applied Pharmacology. 141:1996;195-204.
14. Kaneko T., Tahara S. Formation of 8-oxo-2′-deoxyguanosine in the DNA of human diploid fibroblasts by treatment with linoleic acid hydroperoxide and ferric ion. Lipids. 35:2000;961-965.
15. Kaneko T., Tahara S., Matsuo M. Non-linear accumulation of 8-hydroxy-2′-deoxyguanosine, a marker of oxidized DNA damage during aging. Mutation Research. 316:1996;277-285.
16. Kasai H., Nishimura S. Formation of 8-hydroxydeoxyguanosine in DNA by oxygen radicals and its biological significance. Sies H. Oxidative Stress: Oxidants and Antioxidants. 1991;99-116 Academic Press, London.
17. Kraynak A.R., Storer R.D., Jensen R.D., Kloss M.W., Soper K.A., Clair J.H., DeLuca J.G., Nichols W.W., Eydelloth R.S. Extent and persistence of streptozotocin-induced DNA damage and cell proliferation in rat kidney as determined by in vivo alkaline elution and BrdUrd labeling assays. Toxicology and Applied Pharmacology. 135:1995;279-286.
18. Mitani H., Bandoh T., Ishikawa J., Kimura M., Totsuka T., Hayashi S. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. British Journal of Pharmacology. 119:1996;1269-1275.
19. Miyamae Y., Yamamoto M., Sasaki Y.F., Kobayashi H., Shimoi M., Hayashi K.M. Evalution of a tissue homogenization technique that isolates nuclei for the in vivo single cell gel electrophoresis (comet) assay: a collaborative study by five laboratories. Mutation Research. 418:1998;131-140.
20. Nakamura T., Nishi H., Kokusenya Y., Hirota K., Miura Y. Mechanism of antioxidative activity of fluvastatin-determination of the active position. Chemical and Pharmaceutical Bulletin. 48:2000;235-237.
21. Plosker G.L., Wagstaff A.J. Fluvastatin - a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs. 51:1996;433-459.
22. Sano T., Umeda F., Hashimoto T., Nawata H., Utsumi H. Oxidative stress measurement by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes. Diabetologia. 41:1998;1355-1360.
23. Sasaki Y.F., Tsuda S., Izumiyama F., Nishidate E. Detection of chemically induced DNA lesions in multiple mouse organs (liver, lung, spleen, kidney, and bone marrow) using the alkaline single cell gel electrophoresis (Comet) assay. Mutation Research. 388:1997;33-44.
24. Schmezer P., Eckert C., Liegibel U.M. Tissue-specific induction of mutations by streptozotocin in vivo. Mutation Research. 307:1994;495-499.
25. Shigenaga M.K., Ames B.N. Assay for 8-hydroxy-2′-deoxyguanosine, a biomarker of in vivo oxidative DNA damage. Free Radical Biology and Medicine. 10:1991;211-216.
26. Suzumura K., Yasuhara M., Narita H. Superoxide anion scavenging properties of fluvastatin and its metabolites. Chemical and Pharmaceutical Bulletin. 47:1999;1477-1480.
27. Suzumura K., Yasuhara M., Tanaka K., Odawara A., Narita H., Suzuki T. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, an HMG-CoA reductase inhibitor. Chemical and Pharmaceutical Bulletin. 47:1999;1010-1012.
28. Suzumura K., Yasuhara M., Tanaka K., Suzuki T. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochemical Pharmacology. 57:1999;697-703.
29. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.-C., Sasaki Y.F. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environmental and Molecular Mutagenesis. 35:2000;206-221.
30. Tse F.L., Labbadia D. Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit. Biopharmaceutics and Drug Disposition. 13:1992;285-294.
31. Tse F.L., Smith H.T., Ballard F.H., Nicoletti J. Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey. Biopharmaceutics and Drug Disposition. 11:1990;519-531.
32. Yamamoto A., Hoshi K., Ichihara K. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. European Journal of Pharmacology. 361:1998;143-149.